ERBB2 and breast neoplasm: Ki-67 is expressed in the nucleus during different phases of the cell cycle [35], and was shown to be significantly higher in brain metastases than in the primary breast tumors, being prognostically discriminant for survival in BCBM patients with either HER2 overexpression or TNBC [35,36,37].